Back to Results
First PageMeta Content
NHS Scotland / Pharmacology / Pharmacy / Clinical pharmacology / Scottish Medicines Consortium / Myelofibrosis / Ruxolitinib / Pharmaceuticals policy / Formulary / Medicine / Health / Pharmaceutical sciences


Statement of Advice ruxolitinib (Jakavi®) 5mg, 15mg and 20mg Tablets Novartis Pharmaceuticals UK Ltd (No: 867/13)
Add to Reading List

Open Document

File Size: 39,29 KB

Share Result on Facebook

Company

Tablets Novartis Pharmaceuticals UK Ltd / /

Country

Scotland / /

MedicalCondition

polycythaemia vera myelofibrosis / chronic idiopathic myelofibrosis / essential thrombocythaemia myelofibrosis / primary myelofibrosis / /

Organization

NHS / /

Position

Chairman / /

SocialTag